BIOPHARMA
ByCan Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Can Insilico Medicine and China Medical System Accelerate AI-Discovered Drugs from Algorithm to Clinic?
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
Can Angelini’s $120M AI Alliance with Quiver Bioscience Redefine Drug Discovery in Genetic Epilepsies?
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital or Closed Data Experiment?
Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…
